Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 250K | 0 | 0 |
| Gross Profit | -3K | 0 | 250K | 0 | 0 |
| Operating Income | -18M | -15M | -13M | -16M | -42M |
| EBITDA | -18M | -14M | -12M | -14M | -24M |
| Net Income | -17M | -14M | -12M | -14M | -27M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$1.80
-6.25% today
1Y Change
+150.70%
Window
Jun 26, 2025 → Jun 16, 2026
Coverage: 244 bars · Jun 26, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Palisade Bio, Inc. (PALI) is a Healthcare stock with a market cap of $330.00M and listed on NASDAQ. The stock last traded around $1.80 and up 150.7% across the available one-year price window (Jun 26, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +97.1%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +97.1%, free cash flow +11.0% with operating margin 0.0% and ROIC -13.9%. Stock Foundry combines PALI price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
PALI
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
PALI Max Drawdown
-56.45%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PALI and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$26.6M
-86.6% YoY
Free Cash Flow
-$14.8M
-10.5% YoY
Revenue Growth
+0.0%
EPS Growth
+97.1%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 250K | 0 | 0 |
| Gross Profit | -3K | 0 | 250K | 0 | 0 |
| Operating Income | -18M | -15M | -13M | -16M | -42M |
| EBITDA | -18M | -14M | -12M | -14M | -24M |
| Net Income | -17M | -14M | -12M | -14M | -27M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 133M | 10M | 12M | 12M | 10M |
| Total Assets | 134M | 11M | 14M | 16M | 13M |
| Total Liabilities | 5M | 3M | 3M | 3M | 5M |
| Shareholder Equity | 129M | 7M | 11M | 12M | 7M |
| Total Debt | 71K | 169K | 369K | 404K | 199K |
| Net Debt | -133M | -10M | -12M | -12M | -10M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
15M
-10.6% YoY
Capital Expenditures
0
+100.0% YoY
Free Cash Flow
15M
-10.5% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-47.8%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.